Fisher Patrick sold $1K of OFIX

Fisher Patrick (President, Global Limb Recon) sold 150 shares of Orthofix Medical Inc. (OFIX) at $9.44 on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fisher Patrick
Published Oct 5, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OFIX
Bearish
high confidence
Mentioned
$OFIX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OFIXBearishLow
01

Why it matters

A modest insider sell typically has limited price effect, but traders may watch for any follow‑on activity.

02

Market read

The filing is a routine insider sale with low material impact; relevance is primarily for compliance monitoring.

03

What to watch

Insider retains a large position (over 50,000 shares) and the sale was pre‑arranged, reducing informational value.

Relevance 2/10Novelty 2/10Timing: post‑market filing on Oct 5

Background

SEC Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$OFIXBearishHigh confidence
Context

Form 4 disclosed President Fisher Patrick sold 150 shares for $1,416 via a 10b5‑1 plan.

Expected impact

potential slight downward pressure as market prices the insider sell

Evidence & confidence

The transaction size is modest ($1.4k) and represents a routine 10b5‑1 sale; impact is limited but could cause minor short‑term pressure.

Market effects

Minimal; Orthofix operates in medical devices, a single insider sale does not affect the sector.

None; the filing is company‑specific.

Low; no broader market impact.

Counterpoint

The sale could be a routine liquidity move and not indicative of any negative outlook.

Key entities

  • Orthofix Medical Inc.

    Medical device manufacturer listed on Nasdaq (OFIX).

  • Fisher Patrick

    President, Global Limb Recon at Orthofix.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OFIXHighAI 8/10

Orthofix Earnings Call Shows Growth Amid Spine Challenges

Orthofix Medical reported Q3 revenue of $207.9M, up 2.3% YoY. Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively, while U.S. Spine declined 5%. Adjusted EBITDA improved to $26M. Management lowered 2026 guidance, citing Spine market softness and supply issues, but expects 2027 core revenue growth excluding MDR impact.

Med

Orthofix Medical Inc. Q3 2026 Earnings Call Summary

Orthofix Medical Inc. reported Q3 2026 earnings below expectations due to U.S. Spine market softness and supplier delays. The company is consolidating distributors, with core partners generating 80% of U.S. spinal implant revenue. Updated full-year 2026 revenue guidance is $825M-$830M. Management expects a $22M net sales headwind in 2027 due to European MDR requirements. The VIRATA spinal implant system is set for full market launch in late Q4 2026.

$OFIXMedAI 8/10

Orthofix Medical (OFIX) Q3 2026 Earnings Call Transcript

Orthofix Medical (OFIX) reported Q3 2026 net sales of $207.9M, up 2.3% YoY. Spine sales fell 1%, while Limb Reconstruction and Therapeutic Solutions grew 9% and 4%, respectively. The company is focusing on strategic partnerships, simplifying its product portfolio, and aligning costs. It expects near-term sales pressure due to these transitions and updated guidance accordingly. Cash reserves stood at $86.9M.

$OFIXMed

Orthofix 3Q 2026: Revenue $207.86M, EPS ($0.15) — 10-Q Summary

Orthofix reported 3Q 2026 revenue of $207.86M, up 1.1% YoY, with a net loss of $6.07M, improved from $22.8M last year. Therapeutic Solutions and Global Limb Reconstruction sales grew, while Spinal Implants and other segments declined. Gross margin fell to 70.5% due to product mix changes. SG&A expenses decreased by $22.8M, driven by lower legal costs and commissions.

$OFIXMed

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance LEWISVILLE, Texas — November 9, 2026 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarte